Mitochondrial transplantation emerges as a bold new strategy for treating eye disease
A review of how transferring healthy mitochondria could rescue energy-starved retinal, optic nerve and corneal cells, and what stands in the way of clinical use.
Summary
The eye's retina, optic nerve and cornea depend heavily on mitochondria, which makes them vulnerable to energy failure and oxidative damage. This review covers mitochondrial biology in ocular tissues and explains how mitochondrial dysfunction contributes to conditions such as age-related macular degeneration, diabetic retinopathy, glaucoma, optic neuropathies and corneal dystrophies. It then introduces mitochondrial transplantation (MT), the transfer of healthy mitochondria into struggling cells, as an emerging ocular therapy. MT has shown promise in heart, lung and brain, and early work is now reaching the eye. The authors also flag bottlenecks that must be solved before MT can move from bench to bedside. Note that the text supplied covered only the introductory sections.
Detailed Summary
Why this matters: Vision depends on some of the most energy-hungry tissues in the body. Mitochondrial dysfunction contributes to blinding conditions ranging from rare inherited disorders to common diseases like age-related macular degeneration (AMD), diabetic retinopathy and glaucoma. Individual mitochondrial diseases are rare, but collectively they affect roughly 1 in 4,300 adults, and more than half of affected people have eye involvement such as optic neuropathy, retinal degeneration, ptosis or ophthalmoplegia. Existing mitochondria-targeted treatments are largely supportive, which is why replacing the organelles themselves is attracting interest.
What the review covers: This narrative review from a Singapore group (NUS, A*STAR, Singapore Eye Research Institute) first summarizes mitochondrial structure and function, including the electron transport chain, ROS production, cardiolipin, mtDNA, and quality-control systems such as fusion, fission and mitophagy. It then maps how mitochondria differ across the eye. Retinal ganglion cells and retinal pigment epithelium (RPE) rely heavily on oxidative phosphorylation. Müller cells, corneal stromal fibroblasts and the lens favor glycolysis. Photoreceptors have mitochondria concentrated in their inner segments. The review then moves to disease mechanisms and, per the abstract, to current mitochondria-targeted therapies and the state of ocular MT.
Key points from the available text: Primary mitochondrial diseases arise from germline mutations in any of the 37 mtDNA genes or over 300 nuclear genes. Secondary dysfunction stems from aging, inflammation, light, smoking, diet or mitotoxic drugs. mtDNA lacks histones, has limited repair capacity and sits near ROS-producing complexes, so it mutates 10–20 times more often than nuclear DNA. In the cornea, UVA exposure drives mtDNA damage, and the stroma carries the highest burden of the common 4977-bp deletion. Dry eye and Fuchs endothelial corneal dystrophy involve oxidative stress, fragmented mitochondria, lost membrane potential and caspase-mediated cell death. The text also notes that nature already moves mitochondria between cells: ganglion cell axons shed mitochondria to astrocytes, and photoreceptors can exchange them via tunneling nanotubes. This is the biological rationale for transplantation.
Implications: The abstract describes MT as an emerging ocular therapy with promising outcomes for corneal, optic nerve and retinal disorders, building on success in heart, lung and brain. Because MT supplies functional organelles rather than a single molecule, it could in principle address both genetic and acquired energy failure.
Caveats: The abstract states MT faces several potential bottlenecks before clinical adoption, including questions of delivery, sourcing and durability. The full text provided was truncated after the corneal disorders section, so the detailed ocular MT studies, preclinical models, and the authors' specific challenge and future-direction discussions could not be assessed here. This is a narrative review, not a primary study or trial, and it presents no new clinical data.
Key Findings
- Mitochondrial diseases affect about 1 in 4,300 adults, and over half of patients show ocular manifestations such as optic neuropathy or retinal degeneration.
- mtDNA mutates 10–20 times more often than nuclear DNA because it lacks histones, has weak repair and sits near ROS-generating complexes.
- Retinal ganglion cells and RPE depend heavily on oxidative phosphorylation, making them especially vulnerable to mitochondrial damage.
- Natural intercellular mitochondrial transfer occurs in the retina, via astrocyte uptake of ganglion cell mitochondria and photoreceptor tunneling nanotubes.
- The authors describe ocular mitochondrial transplantation as promising for corneal, optic nerve and retinal disorders but facing translational bottlenecks.
Methodology
This is a narrative review article published in Redox Biology (2025) that synthesizes literature on mitochondrial biology in the eye, mitochondria-targeted therapies, and ocular mitochondrial transplantation. No systematic search methodology or quantitative pooling is described in the text provided.
Study Limitations
The supplied full text was truncated after the corneal disorders section, so this summary relies on the abstract and introductory sections and does not capture the detailed MT study data or the authors' translational analysis. As a narrative review, it carries selection bias and presents no new experimental or clinical evidence, and most ocular MT evidence appears to be preclinical.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: